For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 157,697 | |||
| General and administrative | 21,001 | |||
| Total operating expenses | 178,698 | |||
| Loss from operations | -178,698 | |||
| Interest income | 16,224 | |||
| Other income | 23 | |||
| Total other income | 16,247 | |||
| Net loss | -162,451 | |||
| Basic EPS | -1.87 | |||
| Diluted EPS | -1.87 | |||
| Basic Average Shares | 87,006,027 | |||
| Diluted Average Shares | 87,006,027 | |||
Olema Pharmaceuticals, Inc. (OLMA)
Olema Pharmaceuticals, Inc. (OLMA)